KAI Pharmaceuticals
http://www.kaipharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From KAI Pharmaceuticals
Asia Deal Watch: Orum, Vertex Team Up On Gene Editing Conditioning Agents
Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.
Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery
Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.
Jazz’s Suvecaltamide Fails In Tremor Trial, But Parkinson’s Study Continues
A Phase IIb trial evaluating suvecaltamide failed to show a statistically significant benefit versus placebo on an assessment scale for essential tremor.
BIO: Bayer Operational Model Benefits From Its Arm’s Length Biotechs
There is a lot of structural change going on at the German major but it is learning from the way its wholly owned subsidiaries such as AskBio and BlueRock are run.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice